5,331 results match your criteria Plaque Psoriasis


Association of S100A8/A9 with lipid-rich necrotic core and treatment with biologic therapy in patients with psoriasis: results from an observational cohort study.

J Invest Dermatol 2022 Jun 21. Epub 2022 Jun 21.

Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD. Electronic address:

Psoriasis is a systemic inflammatory disease with increased risk of atherosclerotic events and premature cardiovascular disease. S100A7, A8/A9, and A12 are protein complexes that are produced by activated neutrophils, monocytes, and keratinocytes in psoriasis. Lipid-rich necrotic core (LRNC) is a high-risk coronary plaque feature previously found to be associated with cardiovascular risk factors and psoriasis severity. Read More

View Article and Full-Text PDF

Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry).

J Eur Acad Dermatol Venereol 2022 Jun 24. Epub 2022 Jun 24.

Dermatology and Venereology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine (CMM), Karolinska Institutet, Stockholm, Sweden; Dermatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

Background: The COVID-19 pandemic has raised questions regarding the management of chronic skin diseases, especially in patients on systemic treatments. Data concerning the use of biologics in adults with psoriasis are reassuring, but data specific to children are missing. Moreover, COVID-19 could impact the course of psoriasis in children. Read More

View Article and Full-Text PDF

Association of germline TYK2 variation with lung cancer and non-Hodgkin lymphoma risk.

Int J Cancer 2022 Jun 23. Epub 2022 Jun 23.

Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom.

Deucravacitinib, a novel, selective inhibitor of TYK2 is currently under review at the FDA and EMA for treatment of moderate-to-severe plaque psoriasis. It is unclear whether recent safety concerns (ie, elevated rates of lung cancer and lymphoma) related to similar medications (ie, other JAK inhibitors) are shared with this novel TYK2 inhibitor. We used a partial loss-of-function variant in TYK2 (rs34536443), previously shown to protect against psoriasis and other autoimmune diseases, to evaluate the potential effect of therapeutic TYK2 inhibition on risk of lung cancer and non-Hodgkin lymphoma. Read More

View Article and Full-Text PDF

Modulation of psoriatic-like skin inflammation by traditional Indian medicine Divya-Kayakalp-Vati and Oil through attenuation of pro-inflammatory cytokines.

J Tradit Complement Med 2022 Jul 20;12(4):335-344. Epub 2021 Sep 20.

Drug Discovery and Development Division, Patanjali Research Institute, NH-58, Haridwar, 249405, Uttarakhand, India.

Background And Aim: Psoriasis (Ps) is a chronic skin inflammatory disorder, that progresses to scaly-red dermal plaque formations associated with inflammation. Divya-Kayakalp-Vati (DKV) and Divya-Kayakalp-Oil (DKO) are traditional Ayurveda herbo-mineral formulations, that are prescribed for the treatment of inflammatory dermal ailments. In the present study, we evaluated the efficacy of Divya-Kayakalp-Vati and Divya-Kayakalp-Oil (DKV-O) combined treatment in ameliorating Ps-like skin inflammation under and conditions. Read More

View Article and Full-Text PDF

Oral Administration of East Asian Herbal Medicine for Inflammatory Skin Lesions in Plaque Psoriasis: A Systematic Review, Meta-Analysis, and Exploration of Core Herbal Materials.

Nutrients 2022 Jun 12;14(12). Epub 2022 Jun 12.

Department of Herbal Pharmacology, College of Korean Medicine, Gachon University, 1342 Seongnamdae-ro, Sujeong-gu, Seongnam 13120, Korea.

Psoriasis is an inflammatory autoimmune skin disease with various clinical manifestations. The aim of this review was to systematically evaluate the efficacy and safety of oral administration of East Asian herbal medicine (EAHM) for inflammatory skin lesions in psoriasis and to explore core herbal materials for drug discovery. A comprehensive search was conducted in 10 electronic databases for randomized controlled trials from their inception until 29 July 2021. Read More

View Article and Full-Text PDF

Risks of Biologic Therapy and the Importance of Multidisciplinary Approach for an Accurate Management of Patients with Moderate-Severe Psoriasis and Concomitant Diseases.

Biology (Basel) 2022 May 25;11(6). Epub 2022 May 25.

Department of Dermatology, 'Elias' Emergency University Hospital, 011461 Bucharest, Romania.

Psoriasis is a chronic multisystem inflammatory disease associated with a plethora of comorbidities including metabolic syndrome, cardiovascular disease, hypertension, diabetes, hyperlipidemia, obesity, anxiety, depression, chronic kidney disease, and malignancy. Advancement in unveiling new key elements in the pathophysiology of psoriasis led to significant progress in the development of biologic agents which target different signaling pathways and cytokines involved in the inflammatory cascade responsible for the clinical manifestations found in psoriasis. Currently available novel therapeutic options for moderate-severe psoriasis include tumor necrosis factor alpha inhibitors, inhibitors of the interleukin 17, and inhibitors of the interleukin 23. Read More

View Article and Full-Text PDF

Alteration of gut microbiota during narrowband ultraviolet B therapy: A preliminary study.

Exp Dermatol 2022 Jun 23. Epub 2022 Jun 23.

Department of Dermatology, Erasmus University Medical Center, Rotterdam.

Background: Gut microbiome dysbiosis is associated with psoriasis development. A relationship between gut microbiota and psoriasis treatment response has been reported. No study has reported the effect of narrowband ultraviolet B (NBUVB) therapy, a standard treatment of psoriasis, on gut microbiota. Read More

View Article and Full-Text PDF

Combination Therapy with Apremilast and Biologics for Psoriasis: A Systematic Review.

Am J Clin Dermatol 2022 Jun 23. Epub 2022 Jun 23.

Department of Dermatology, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Nielsine Nielsens Vej 9, 2300, Copenhagen, Denmark.

Background: The evidence for adding small-molecule drugs to an ongoing biologic treatment is sparse, but combination therapies appear to be advantageous in appropriately selected patients with psoriasis. To our knowledge, efficacy and safety of combination therapy with apremilast and biologics has not previously been reviewed.

Materials And Methods: A literature search was performed on Medline (PubMed), Embase, Web of Science, and the Cochrane Library. Read More

View Article and Full-Text PDF

Two cases of Erythrodermic psoriasis treated with Golimumab.

Ann Med Surg (Lond) 2022 Jun 8;78:103961. Epub 2022 Jun 8.

Faculty of Medicine, Syrian Private University, Damascus, Syria.

Introduction And Importance: Erythrodermic psoriasis (EP) is a very severe subtype of psoriasis, with a challenge poses in its treatment, as currently available therapies often provide unsatisfactory results, for those many biologics have been used in the treatment of EP such as Golimumab which has been extensively studied for the treatment of psoriatic arthritis, and chronic plaque psoriasis. However, no clinical trials have been performed for EP.

Case Presentation: We report two cases of a 23-year old female, and a 31-year male who presented with severe psoriasis that previously un respond to ultraviolet B phototherapy, methotrexate, cyclosporine, and topical agents. Read More

View Article and Full-Text PDF

A Pilot Study to Assess the Reliability of Digital Image-Based PASI Scores Across Patient Skin Tones and Provider Training Levels.

Dermatol Ther (Heidelb) 2022 Jun 21. Epub 2022 Jun 21.

Department of Dermatology, University of California, 2340 Sutter Street, Box 0808, San Francisco, CA, 94143, USA.

Introduction: The ability to perform psoriasis skin assessments remotely through digital image-based psoriasis area and severity index (DIB-PASI) would be a valuable tool for psoriasis clinical trials. An ideal teledermatological assessment would be robust across patients of diverse skin tones as well as across assessors of varying experience levels. In this pilot study, we evaluated the reliability of face-to-face (FTF) versus DIB-PASI scores determined by trained clinical assessors with a spectrum of experience and with patients of different skin tones. Read More

View Article and Full-Text PDF

Treatment of chronic plaque psoriasis with herbal Unani formulations: A randomized control trial of efficacy and safety.

J Ethnopharmacol 2022 Jun 17;296:115456. Epub 2022 Jun 17.

Drug Standardization Unit, National Research Institute of Unani Medicine, for Skin Disorders (NRIUMSD), Hyderabad, 500038, India. Electronic address:

Ethnopharmacological Relevance: Psoriasis, despite modern therapeutic options, is incurable and recurrent. In Unani (Greco-Arab) medicine, many medications and formulations have been prescribed by eminent scholars for conditions clinically similar to psoriasis, though empirical evidence is sparse. Hence, the experimental formulations ItrīfalShāhtra and MarhamḤina were chosen to be compared to the standard therapies PUVAsol and petrolatum for their safety and efficacy. Read More

View Article and Full-Text PDF

Anti-IL-17A ssDNA aptamer ameliorated psoriasis skin lesions in the imiquimod-induced psoriasis mouse model.

Int Immunopharmacol 2022 Jun 17;110:108963. Epub 2022 Jun 17.

Immunology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address:

Objectives: IL-17 is an important player in the psoriasis pathogenesis, which recruits inflammatory cells to the psoriatic lesions, induced keratinocyte proliferation and plaque formation. Three monoclonal antibodies that block IL-17 have been approved for psoriasis treatment in the last decade. Compared to monoclonal antibodies, aptamers which are single-stranded DNA or RNA, bind with high affinity to proteins or other molecules and are more cost-effective. Read More

View Article and Full-Text PDF

Comparison of Th1 and Th17 Inflammatory Cytokine Profiles Between Chronic Plaque and Acute Guttate Psoriasis.

Ann Dermatol 2022 Jun 20;34(3):200-205. Epub 2022 May 20.

Department of Dermatology, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea.

Background: The phenotypic heterogeneity of psoriasis is suspected to reflect differences in its pathogenesis, but not yet completely elucidated. Studies of the Th1 and Th17 cytokines associated with different phenotypes of psoriasis have yielded inconsistent results.

Objective: To investigate the tissue expression levels of Th1 and Th17 cytokines among patients with chronic plaque psoriasis, acute guttate psoriasis, and healthy control. Read More

View Article and Full-Text PDF

Association Between Short-Term PASI90 Achievement and Drug Survival of Biologics in Patients with Psoriasis.

Ann Dermatol 2022 Jun 20;34(3):173-181. Epub 2022 May 20.

Department of Dermatology, SMG-SNU Boramae Medical Center, Seoul, Korea.

Background: With accumulating evidence that achieving a 90% improvement in the Psoriasis Area and Severity Index score (PASI90) has better correlation with improved health-related quality of life as compared to PASI75 achievement, there has been demand for establishing new treatment goals for psoriasis. We investigated whether the short-term PASI90 achievement would predict longer drug survival as compared to PASI75 achievement.

Objective: We investigated whether the short-term PASI90 achievement would predict longer drug survival as compared to PASI75 achievement. Read More

View Article and Full-Text PDF

Full-Length Transcriptome Sequencing Analysis of Differentially Expressed Genes and Pathways After Treatment of Psoriasis With Oxymatrine.

Front Pharmacol 2022 3;13:889493. Epub 2022 Jun 3.

Department of Dermatovenereology, The General Hospital of Ningxia Medical University, Yinchuan, China.

Psoriasis is a recurrent chronic inflammatory skin disease. Unlike many of the latest psoriasis treatments that only confer limited curative effects and have certain side effects, oxymatrine effectively improves severe plaque psoriasis with mild adverse reactions. Here, we explored the genes and pathways underlying the effects of oxymatrine on psoriasis. Read More

View Article and Full-Text PDF

PET/CT-Based Characterization of 18F-FDG Uptake in Various Tissues Reveals Novel Potential Contributions to Coronary Artery Disease in Psoriatic Arthritis.

Front Immunol 2022 2;13:909760. Epub 2022 Jun 2.

National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, United States.

Background And Objectives: Psoriasis is a heterogeneous inflammatory disease that involves the skin, joints, liver, heart, and other organs. Psoriatic arthritis (PsA) is associated with cardiovascular disease (CVD), but the relative contributions of inflammatory and metabolic dysregulation to CVD are incompletely understood. We set out to discover novel potential contributors to CVD in PsA patients by comprehensively phenotyping a cohort of PsA patients using these advanced technologies. Read More

View Article and Full-Text PDF

Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year.

Expert Opin Biol Ther 2022 Jun 22:1-8. Epub 2022 Jun 22.

Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.

Background: Real-world data on guselkumab, especially at times >6 months, are limited.

Research Design And Methods: We performed a longitudinal, retrospective analysis on 307 patients with moderate-severe chronic plaque psoriasis (Psoriasis Area Severity Index [PASI] >10) treated with guselkumab for up to 12 months.

Main Outcome Measures: PASI 75, PASI 90, and PASI 100 were assessed at baseline and at 4, 12, 20, 28, 36, 44, and 52 weeks. Read More

View Article and Full-Text PDF

Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge.

Psoriasis (Auckl) 2022 8;12:127-137. Epub 2022 Jun 8.

Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, 80131, Italy.

Bimekizumab, a novel humanized monoclonal IgG1 antibody that neutralizes both IL-17A and IL-17F, was recently approved the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Bimekizumab represents the latest anti IL-17 treatment available for the management of moderate to severe psoriasis. Bimekizumab safety and efficacy profiles were evaluated in four Phase III clinical trials, which evaluated bimekizumab versus placebo and ustekinumab (BE VIVID), versus placebo (BE READY), versus adalimumab (BE SURE), and versus secukinumab (BE RADIANT). Read More

View Article and Full-Text PDF

A case of de novo annular-plaque type psoriasis following Oxford-AstraZeneca COVID-19 vaccination.

Curr Drug Saf 2022 Jun 13. Epub 2022 Jun 13.

Department of Dermatology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India 492099.

Background There have been increasingly reported cases of new-onset or aggravation of pre-existing dermatoses after the implementation of COVID-19 vaccination. Case Presentation An elderly male presented with multiple annular scaly plaques all over the body two weeks following administration of the first dose of Oxford-AstraZeneca COVID-19 vaccine. The lesions further aggravated after taking the second dose of the vaccine. Read More

View Article and Full-Text PDF

Beyond plaque psoriasis - pathogenesis and treatment of other psoriasis phenotypes.

Curr Opin Rheumatol 2022 Jun 10. Epub 2022 Jun 10.

Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma, Barcelona, Spain.

Purpose Of Review: Psoriasis vulgaris is the commonest presentation of psoriatic disease, but morphologic variants such as pustular psoriasis (PP) and a closely related disease, pityriasis rubra pilaris (PRP), have been known for a long time, have been associated with rheumatologic manifestations indistinguishable from psoriatic arthritis (PsA) that may go unrecognized, and often represent a therapeutic conundrum. There is recent evidence that underlying genetic and pathogenetic differences may provide the basis for newer therapeutic approaches.

Recent Findings: This narrative review highlights the clinical, genetic and pathogenetic characteristics of PP and PRP, their association with PsA and recent developments in their treatment, especially with biologic agents targeting IL-36 and other cytokines of pathogenic relevance. Read More

View Article and Full-Text PDF

Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study.

Paediatr Drugs 2022 Jul 13;24(4):377-387. Epub 2022 Jun 13.

Novartis Pharma AG, Basel, Switzerland.

Background: The efficacy and safety of biologic treatments for children and adolescents with moderate to severe psoriasis should be examined over a considerable time period and in different subgroups.

Objective: We report the efficacy and safety of secukinumab low dose (LD) and high dose (HD) regimens in pediatric patients with moderate to severe psoriasis for up to Week 52.

Methods: This was a randomized, open-label, parallel-group, multicenter study in patients aged  6 to < 18 years. Read More

View Article and Full-Text PDF

Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate to severe plaque psoriasis: long-term results from an interim analysis of the SERENA study.

J Eur Acad Dermatol Venereol 2022 Jun 13. Epub 2022 Jun 13.

Novartis Pharma AG, Basel, Switzerland.

Background: Randomised controlled trials of secukinumab have shown sustained efficacy and a favourable safety profile in multiple manifestations of psoriatic disease.

Objectives: To assess the long-term, real-world retention, effectiveness, and safety of secukinumab in routine clinical practice for the treatment of moderate to severe plaque-type psoriasis (PsO).

Methods: SERENA (CAIN457A3403) is a large, ongoing, longitudinal, observational study conducted at 438 sites and 19 countries across Europe for an expected duration of up to 5 years in adult patients with moderate to severe PsO, psoriatic arthritis, and ankylosing spondylitis. Read More

View Article and Full-Text PDF

The relationship between histomorphological findings and platelet activation in psoriasis.

J Cosmet Dermatol 2022 Jun 13. Epub 2022 Jun 13.

Necmettin Erbakan University, Faculty of Medicine, Department of Pathology, Konya, Turkey.

Background: Elevated platelet count (PC), Mean Platelet Volume (MPV), and Platelet Mass Index (PMI) are reported in patients with psoriasis, while platelet activation is associated with psoriasis severity. Available studies examining the relationship between platelet activation markers and psoriasis have mostly focused on psoriasis area severity index. To the best of our knowledge, there is no study examining the relationship between histopathological features of a single psoriatic plaque and platelet activation. Read More

View Article and Full-Text PDF

On and off-label uses of interleukin-17 inhibitors for patients with plaque-type psoriasis in Thailand: a real-world study.

J Dermatolog Treat 2022 Jun 23:1-12. Epub 2022 Jun 23.

Faculty of Medicine, Division of Dermatology, Department of Medicine, Chulalongkorn University, Bangkok, Thailand.

Background: Off-label uses of biologics in the treatment of psoriasis are usually implemented in limited-resource settings and studies regarding their response profiles are limited.

Method: This was a retrospective study performed in moderate-to-severe plaque-type psoriasis patients who had been treated with either secukinumab, ixekizumab or brodalumab at a university hospital in Thailand between 1 January 2017 and 1 April 2021.

Results: A total of 142 patients were included in the data analysis consisting of three groups of 48 patients, 86 patients, and 8 patients treated by secukinumab, ixekizumab, and brodalumab, respectively. Read More

View Article and Full-Text PDF

Generalized pustular psoriasis: the new era of treatment with IL-36 receptor inhibitors.

J Dermatolog Treat 2022 Jun 21:1-8. Epub 2022 Jun 21.

Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal.

Generalized pustular psoriasis (GPP) is a rare yet severe variant of psoriasis, characterized by the eruption of superficial sterile pustules that appear suddenly and widely distributed, potentially life-threatening. It more commonly presents through recurrent acute flares triggered by stress, corticosteroid withdrawals, pregnancy, or infections. The pathogenesis of this disease is yet to be fully understood. Read More

View Article and Full-Text PDF

Efficacy and Safety of Apremilast in the Treatment of Patients with Mild-to-Moderate Psoriasis in Japan: Results from PROMINENT, A Phase 3b, Open-Label, Single-Arm Study.

Dermatol Ther (Heidelb) 2022 Jun 11;12(6):1469-1480. Epub 2022 Jun 11.

Sapporo Skin Clinic, Sapporo, Japan.

Introduction: Patients with mild-to-moderate plaque psoriasis often experience reduced quality of life and increased disease burden due to itch or involvement of psoriasis in special areas such as the scalp and nails. Systemic therapy may be used concurrently with topical therapy in patients with active disease not controlled by topical therapy alone. The objective of PROMINENT was to evaluate the efficacy and safety of apremilast in combination with topical therapy in patients with mild-to-moderate psoriasis in Japan. Read More

View Article and Full-Text PDF

Enhanced Effect of Qing-Ying Decoction Concurrent with Secukinumab in the Treatment of Plaque Psoriasis.

Altern Ther Health Med 2022 Jun 10. Epub 2022 Jun 10.

Both Qing-Ying decoction (QYD), a Traditional Chinese Medicine (TCM), and secukinumab, a fully humanized anti-interleukin-17A monoclonal antibody, have been used to treat patients with plaque psoriasis. The combined application of TCM and biologics in the treatment of psoriasis, however, has not been investigated. We enrolled a total of 68 patients with plaque psoriasis in our prospective study, and randomly assigned them to either the study group (treated with secukinumab plus QYD), or the control group (treated with secukinumab alone). Read More

View Article and Full-Text PDF

Psoriasis and Cardiovascular Diseases: An Immune-Mediated Cross Talk?

Front Immunol 2022 24;13:868277. Epub 2022 May 24.

Unit of Dermatology, Department of Medicine - DIMED, University of Padova, Padova, Italy.

Psoriasis is a chronic immune-mediated inflammatory skin disease, characterized by well-demarcated scaly, erythematous, infiltrated plaques. The cutaneous-to-systemic expansion of the inflammation in psoriasis leads to the concept of "psoriatic march" or "inflammatory skin march". Accordingly, psoriasis is thought to be a systemic inflammatory disease associated with numerous comorbidities. Read More

View Article and Full-Text PDF

Demographic aspects, clinical characteristics, and therapeutic approaches in geriatric psoriasis: A study from a tertiary center.

Dermatol Ther 2022 Jun 9:e15628. Epub 2022 Jun 9.

Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Background: Geriatric psoriasis, due to its unusual clinical manifestations and higher rates of systemic complications in this age group, is a challenging issue for dermatologists. Therefore, we aimed to provide an overview of the epidemiological, clinical and therapeutic consequences among patients aged over 60 years with psoriasis in a referral center in Iran.

Materials And Methods: This cross-sectional study was conducted on 156 patients over 60 years with the definitive diagnosis of psoriasis that were referred to our center between 2015 and 2019. Read More

View Article and Full-Text PDF